

# Increased Risk of Type 2 Diabetes in Alzheimer Disease

Juliette Janson,<sup>1,2</sup> Thomas Laedtke,<sup>1</sup> Joseph E. Parisi,<sup>2</sup> Peter O'Brien,<sup>3</sup> Ronald C. Petersen,<sup>4</sup> and Peter C. Butler<sup>5</sup>

Alzheimer disease and type 2 diabetes are characterized by increased prevalence with aging, a genetic predisposition, and comparable pathological features in the islet and brain (amyloid derived from amyloid  $\beta$  protein in the brain in Alzheimer disease and islet amyloid derived from islet amyloid polypeptide in the pancreas in type 2 diabetes). Evidence is growing to link precursors of amyloid deposition in the brain and pancreas with the pathogenesis of Alzheimer disease and type 2 diabetes, respectively. Given these similarities, we questioned whether there may be a common underlying mechanism predisposing to islet and cerebral amyloid. To address this, we first examined the prevalence of type 2 diabetes in a community-based controlled study, the Mayo Clinic Alzheimer Disease Patient Registry (ADPR), which follows patients with Alzheimer disease versus control subjects without Alzheimer disease. In addition to this clinical study, we performed a pathological study of autopsy cases from this same community to determine whether there is an increased prevalence of islet amyloid in patients with Alzheimer disease and increased prevalence of cerebral amyloid in patients with type 2 diabetes. Patients who were enrolled in the ADPR (Alzheimer disease  $n = 100$ , non-Alzheimer disease control subjects  $n = 138$ ) were classified according to fasting glucose concentration (FPG) as nondiabetic (FPG <110 mg/dl), impaired fasting glucose (IFG, FPG 110–125 mg/dl), and type 2 diabetes (FPG >126 mg/dl). The mean slope of FPG over 10 years in each case was also compared between Alzheimer disease and non-Alzheimer disease control subjects. Pancreas and brain were examined from autopsy specimens obtained from 105 humans (first, 28 cases of Alzheimer disease vs. 21 non-Alzheimer disease control subjects and, second, 35 subjects with type 2 diabetes vs. 21 non-type 2 diabetes control subjects) for the presence of islet and brain amyloid. Both type 2 diabetes (35% vs. 18%;  $P < 0.05$ ) and IFG (46% vs. 24%;  $P < 0.01$ ) were more prevalent in Alzheimer disease versus non-Alzheimer

disease control subjects, so 81% of cases of Alzheimer disease had either type 2 diabetes or IFG. The slope of increase of FPG with age over 10 years was also greater in Alzheimer disease than non-Alzheimer disease control subjects ( $P < 0.01$ ). Islet amyloid was more frequent ( $P < 0.05$ ) and extensive ( $P < 0.05$ ) in patients with Alzheimer disease than in non-Alzheimer disease control subjects. However, diffuse and neuritic plaques were not more common in type 2 diabetes than in control subjects. In cases of type 2 diabetes when they were present, the duration of type 2 diabetes correlated with the density of diffuse ( $P < 0.001$ ) and neuritic plaques ( $P < 0.01$ ). In this community cohort from southeast Minnesota, type 2 diabetes and IFG are more common in patients with Alzheimer disease than in control subjects, as is the pathological hallmark of type 2 diabetes, islet amyloid. However, there was no increase in brain plaque formation in cases of type 2 diabetes, although when it was present, it correlated in extent with duration of diabetes. These data support the hypothesis that patients with Alzheimer disease are more vulnerable to type 2 diabetes and the possibility of linkage between the processes responsible for loss of brain cells and  $\beta$ -cells in these diseases. *Diabetes* 53: 474–481, 2004

The islet of Langerhans in type 2 diabetes is characterized by  $\beta$ -cell loss (1,2) and islet amyloid derived from islet amyloid polypeptide (IAPP) (3–5), a protein coexpressed and secreted with insulin by  $\beta$ -cells. Brain dysfunction in Alzheimer disease is characterized by loss of neocortical neurons (6) and focal amyloid deposits, which consist of the locally expressed amyloid  $\beta$  protein (A $\beta$ P) (7–13). The prevalence of both Alzheimer disease and type 2 diabetes increases with age, and both have genetic components (14–19).

A $\beta$ P and IAPP both spontaneously form into amyloid aggregates in an aqueous environment (7,8,20,21). The role of these aggregates of IAPP and A $\beta$ P in  $\beta$ -cell and cortical neuronal death in type 2 diabetes and Alzheimer disease is controversial. Small amyloid aggregates of either of these proteins are cytotoxic (22–25). The mechanism of the cytotoxicity mediated by small protein aggregates has been hypothesized to be by induction of membrane damage (25–27). In the case of IAPP, evidence exists to suggest that abnormal aggregation occurs initially intracellularly, and after cell death, IAPP-derived fibrils accumulate extracellularly (24,28,29). Similar mechanisms are also possible in Alzheimer disease. In vivo, even though IAPP and A $\beta$ P are present in an aqueous environment, in health neither protein forms fibrils, suggesting that mechanisms

From the <sup>1</sup>Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota; the <sup>2</sup>Department of Pathology, Mayo Clinic, Rochester, Minnesota; the <sup>3</sup>Department of Biostatistics, Mayo Clinic, Rochester, Minnesota; the <sup>4</sup>Department of Neurology and Health Sciences Research, Mayo Clinic, Rochester, Minnesota; and the <sup>5</sup>Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, Los Angeles, California.

Address correspondence and reprint requests to Dr. Peter C. Butler, Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, 1333 San Pablo Street, BMT-B11, Los Angeles, CA 90033. E-mail: pbutler@usc.edu.

Received for publication 13 August 2003 and accepted in revised form 27 October 2003.

R.C.P. is on an advisory panel for Elam Pharmaceuticals; has received honoraria from Pfizer, Eisai, Novartis, and Janssen; and has received grant/research support from the National Institute on Aging, Pfizer, and Eisai.

A $\beta$ P, amyloid  $\beta$  protein; ADPR, Alzheimer Disease Patient Registry; FPG, fasting plasma glucose; IAPP, islet amyloid polypeptide; IFG, impaired fasting glucose; NFT, neurofibrillary tangle.

© 2004 by the American Diabetes Association.

exist to prevent this otherwise spontaneous process. These mechanisms likely include the chaperone protein pathway, a system for protein trafficking via intracellular binding proteins (chaperone proteins), which bind nascent proteins and facilitate their transport within the cell (30).

We have previously hypothesized that IAPP amyloid formation in type 2 diabetes may occur under circumstances of genetic variance, which results in a relative decreased affinity of the chaperone protein pathway for trafficking of IAPP (31). It is plausible that a low affinity for binding by one or more chaperone proteins to IAPP may be shared with a similar low affinity for binding to A $\beta$ P. In support of this hypothesis, Schwartz (32) suggested that there might be a relationship between amyloid deposits in the brain and pancreatic islets.

We used both clinical studies (in living patients and community-based control subjects) and pathological studies to examine the existence of a shared risk for Alzheimer disease and type 2 diabetes. In the clinical studies, we took advantage of a unique community-based (Olmsted County, MN) cohort of well-characterized patients with Alzheimer disease and control subjects without Alzheimer disease (33) to address the question, "Is type 2 diabetes more common in Alzheimer disease?" In the pathology studies, we studied brain and pancreas in autopsy cases from the same community to address the hypotheses 1) that islet amyloid is more frequent in patients with Alzheimer disease than in control subjects without Alzheimer disease and 2) that amyloid deposits are more common in the brain in patients with type 2 diabetes than in nondiabetic humans.

## RESEARCH DESIGN AND METHODS

### Clinical studies

The primary objective of the Mayo Clinic Alzheimer Disease Patient Registry (ADPR) was to acquire a cohort of patients with Alzheimer disease and matched non-Alzheimer disease control subjects for assessment of the progression of Alzheimer disease clinically with respect to imaging and other neurological studies. Patients who were from southeastern Minnesota and had dementia were identified at the time of routine general medical examination in the Department of Community Internal Medicine at the Mayo Clinic. All studies were approved by the Mayo Clinic Institutional Review Board. When there was a suspicion of Alzheimer disease during a routine periodic medical examination, a neurological evaluation that included the Mini-Mental State Exam, Geriatric Depression Scale, Hachinski Ischemic Scale, Short Test of Mental Status, Record of Independent Living, and extensive neuropsychological testing was performed (33). Age- and sex-matched control subjects were randomly identified from the same community clinics. All enrolled cases had detailed evaluation to confirm or rule out (control subjects) Alzheimer disease. Once a patient had been enrolled in the ADPR as a case of Alzheimer disease or as a control, he or she was followed annually for clinical studies that included a fasting blood glucose measurement. Recruitment to the ADPR was haphazard (i.e., not deliberately biased) with respect to the presence or absence of diabetes or the blood glucose concentration. Exclusion criteria were 1) chronic treatment with glucocorticoids, 2) a history of pancreatitis, or 3) type 1 diabetes. The distinction between type 1 and type 2 diabetes was made on conventional clinical criteria. The features favoring type 1 diabetes included lean BMI (and further weight loss) and young age at onset, insulin requirement at onset, documented ketoacidosis, presence of other autoimmune diseases, and a family history of autoimmune disease. Features favoring type 2 diabetes included strong family history, prolonged insulin-independent treatment, obesity, absence of autoimmune diseases, and later age of onset. It is acknowledged that the distinction between type 1 and type 2 diabetes is not without error, but in view of the large number of cases in the present studies and the high prevalence of type 2 versus type 1 diabetes, it is unlikely that the conclusions of the present studies have been influenced by erroneous inclusion of cases of type 1 diabetes (Table 1).

**Protocol 1: is type 2 diabetes more common in Alzheimer disease?** These recruitment criteria provided a total of 100 patients with Alzheimer

TABLE 1  
Study cases: clinical studies

	<i>n</i>	Female	Male	Age (years)	BMI (kg/m <sup>2</sup> )
Alzheimer disease	100	72	28	78 ± 9	25.5 ± 4.4
Non-Alzheimer disease	138	110	28	79 ± 7	26.8 ± 4.6

Data are means ± SD.

disease and 138 non-Alzheimer disease control subjects. In protocol 1, these cases and control subjects were classified according to the criteria of the American Diabetes Association into one of three groups: nondiabetic (< 110 mg/dl), impaired fasting glucose (IFG; 110–125 mg/dl), and type 2 diabetes (>126 mg/dl) based on the most recent glucose concentration measurements. Individuals who were taking blood glucose-lowering treatment for diabetes were classified as type 2 diabetes regardless of their most recent fasting glucose concentration.

**Protocol 2: is the increase in fasting plasma glucose with age greater in Alzheimer disease?** We also examined the changes in fasting plasma glucose (FPG) with aging in this cohort of patients. For each subject, we regressed the annual median FPG value against age. This was used to obtain a predicted FPG value for each subject at each decade and also to compare the slopes of the regression lines between groups (Alzheimer disease versus control subjects), using a two-sided rank sum test. To be included in this analysis, patients were required to have FPG values recorded that spanned at least 10 consecutive years from age 50 or greater and at least one value available for each calendar year. Ages of ≥50 years only were considered. These criteria resulted in a study population of 52 patients with Alzheimer disease and 105 non-Alzheimer disease control subjects.

### Pathology studies

**Case recruitment.** Alzheimer disease patients (group 1) and control subjects (non-Alzheimer disease; group 2) had been enrolled in the Mayo Clinic ADPR study during life (33). At death, non-Alzheimer disease and Alzheimer disease cases had an autopsy examination of the brain and the diagnosis of Alzheimer disease (or its absence) was confirmed using CERAD (Consortium to Establish a Registry for Alzheimer Disease) criteria (34). In the pathology study, we include 1) only cases with clinically and pathologically confirmed Alzheimer disease or non-Alzheimer disease, 2) cases with an autopsy including both brain and pancreas, and 3) cases with FPG documented at the Mayo Clinic within 2 years (Alzheimer disease 100%, non-Alzheimer disease 100%) and in most cases 1 year (non-Alzheimer disease 100%, Alzheimer disease 89% of complete autopsies) of death. A mean FPG value for each subject was the mean of at least two independent measurements. Alzheimer disease patients were sex- and age-matched with control subjects during life as per the Mayo Clinic ADPR study and were still matched for age at death (84 ± 8 vs. 85 ± 4 years, Alzheimer disease vs. non-Alzheimer disease; *P* = 0.7). Alzheimer disease was diagnosed 5.5 ± 2.4 (range 1.3–9.9) years before death.

Type 2 diabetes cases (group 3; FPG >126 mg/dl) were identified via Mayo Clinic autopsy records. For inclusion they 1) had died in the 6 years preceding this study, 2) were also from Olmsted County, 3) had an autopsy including both brain and pancreas, and 4) had had a general medical examination performed including an FPG at Mayo Clinic during the year before death. Exclusion criteria included inadequate preservation of pancreatic tissue for anatomic study, type 1 diabetes, or secondary causes of diabetes. Diagnosis of diabetes in this cohort was 12 ± 9 years before death. These selection criteria yielded 35 cases, but the mean age at death was younger in type 2 diabetes than the in Alzheimer disease cases (73 ± 8 vs. 84 ± 8 years; *P* < 0.001). Therefore, identified from the Mayo Clinic autopsy records was an additional control group consisting of 21 cases (group 4) who were age, BMI, and sex matched with type 2 diabetic patients, had a normal FPG documented within 1 year before death, and were also meeting criteria 1–4 as for group 3. Groups 3 and 4 were included haphazardly (i.e., not consciously biased) with respect to the presence or absence of Alzheimer disease. The characteristics of each of these four study groups are summarized in Table 2.

**Protocol 3: is islet amyloid increased in patients with Alzheimer disease?** To address this question, we studied pancreas samples obtained at autopsy in 28 cases with Alzheimer disease and 21 without Alzheimer disease (groups 1 and 2 in Table 2). In addition, 35 cases with type 2 diabetes and 21 without type 2 diabetes were studied as a point of reference. Protocol 3 included a total of 105 cases.

**Protocol 4: is brain amyloid more common in patients with type 2 diabetes?** To address this question, we studied brain samples in 28 cases with and 19 without type 2 diabetes (groups 3 and 4 in Table 2). As a reference, 26

TABLE 2  
Study cases: pathology

Group		<i>n</i>	Female	Male	Age (years)	Weight (kg)	BMI (kg/m <sup>2</sup> )
<b>Pancreas</b>							
1	Alzheimer disease	28	19	9	83.9 ± 7.7	63.5 ± 13.6	24.3 ± 3.4
2	Non-Alzheimer disease	21	12	9	84.8 ± 4.4	70.5 ± 16.8	27.1 ± 6.7
3	Type 2 diabetes	35	15	20	72.7 ± 7.8	83.0 ± 22.9	29.8 ± 6.5
4	Non-type 2 diabetes	21	9	12	72.1 ± 9.1	76.9 ± 11.4	27.2 ± 3.5
<b>Brain</b>							
1	Alzheimer disease	26	18	8	84.2 ± 7.8	62.8 ± 13.5	24.1 ± 3.5
2	Non-Alzheimer disease	19	11	8	84.4 ± 4.3	70.7 ± 17.7	27.4 ± 7.0
3	Type 2 diabetes	28	12	16	72.5 ± 7.8	80.2 ± 21.9	29.5 ± 6.3
4	Non-type 2 diabetes	19	9	10	72.0 ± 9.2	77.0 ± 11.8	27.6 ± 3.4

Data are means ± SD.

cases with Alzheimer disease and 19 without Alzheimer disease were studied. Some paraffin blocks of the superior/midfrontal gyrus were not available, resulting in 92 cases entering protocol 4.

**Light microscopy.** Pancreas and brain samples were obtained at autopsy from the four groups described above. Slides were examined blinded to the identity of the case by light microscopy.

**Pancreas.** Sequential sections obtained from paraffin-embedded pancreas tail samples were stained with hematoxylin/eosin and Congo red and by immunostaining for insulin (29). The nature of pink amyloid deposits in Congo red-stained slides was confirmed by green/orange birefringence under polarized light. At least 25 islets per specimen were scored for presence and extent of islet amyloid. The extent of amyloid deposition was classified per islet on a scale from 0 to 4, with 0 = no deposits, 1 = one deposit, 2 = a few small deposits, 3 = major deposition, and 4 = just a few endocrine cells left between confluent deposits.

**Brain.** Samples of the superior/midfrontal gyrus were collected, and the density of neuritic and diffuse plaques and neurofibrillary tangle (NFT) was determined. For visualizing neurofilaments, paraffin sections of the superior/midfrontal gyrus were stained with a modified Bielschowsky's technique. Per sample, the number of neuritic plaques, diffuse plaques, and NFT was determined in five microscope fields of 2 mm<sup>2</sup> each.

#### Statistical analysis

**Protocols 1 and 2.** A rank sum test was used to compare age, and  $\chi^2$  tests were used to compare number in groups according to classification for sex and diabetic, nondiabetic, or IFG status. A two-sided rank sum test was used to compare slope of fasting glucose versus age.

**Protocols 3 and 4.** An unpaired two-tailed Student's *t* test was used to compare age and BMI between groups. The nonparametric Mann-Whitney test was used to compare the frequency and extent of islet amyloid; FPG; and density of neuritic plaques, diffuse plaques, and NFT among groups. The  $\chi^2$  test was used to compare the number of Alzheimer disease and non-Alzheimer disease subjects with type 2 diabetes. Spearman rank correlations were used to examine relationships among diffuse plaques, neuritic plaques, and NFT density versus duration of diabetes before death and age at death in type 2 diabetes.

## RESULTS

### Clinical studies: prevalence of type 2 diabetes and IFG in the living cohort of Alzheimer disease versus non-Alzheimer disease control subjects and trend of FPG with aging

**Protocol 1.** There was no difference in age or sex distribution between the Alzheimer disease and non-Alzheimer disease control group (Table 1). BMI was slightly but not significantly higher in control subjects versus Alzheimer disease. The prevalence of both type 2 diabetes (34.6 vs. 18.1%;  $P < 0.05$ ) and IFG (46.2 vs. 23.8%;  $P < 0.01$ ) was greater in the Alzheimer disease versus the non-Alzheimer disease control group (Fig. 1); 81% of the Alzheimer disease cases therefore had either type 2 diabetes or IFG. **Protocol 2.** When the trend of FPG with aging was examined, there was a gradual increase with aging in both

groups ( $P < 0.01$  vs. no change). However, the Alzheimer disease group had a greater increase per year compared with non-Alzheimer disease control subjects ( $0.83$  vs.  $0.57$  mg · dl<sup>-1</sup> · y<sup>-1</sup>;  $P < 0.01$ ; Fig. 1). This greater rate of increase of blood glucose was preserved in Alzheimer disease when cases with diabetes were excluded from the analysis.




FIG. 1. Protocol 1: the prevalence of diabetes and IFG in the Olmsted County community-based cohort of cases of Alzheimer disease (AD) and control subjects (non-Alzheimer disease [non-AD]; top). Protocol 2: the slope of FPG concentration versus age in the same cohort (bottom). TTDM, type 2 diabetes.






FIG. 2. Protocol 3: frequency of islet amyloid (*top*) and extent of islet amyloid (*bottom*) in patients with Alzheimer disease (AD) and control subjects (non-Alzheimer disease [non-AD]) and in patients with type 2 diabetes (TTDM) and their control group (non-TTDM). Individual values (●) and medians (line).

#### Pathology studies: islet amyloid in Alzheimer disease (protocol 3) and brain amyloid in type 2 diabetes (protocol 4)

**Protocol 3: islet amyloid in Alzheimer disease.** Both the frequency and the extent of islet amyloid were higher in the Alzheimer disease group versus the non-Alzheimer disease group (both  $P < 0.05$ ; Fig. 2) despite a trend toward a lower BMI in Alzheimer disease ( $24.3 \pm 3.4$  vs.  $27.1 \pm 6.7$  kg/m<sup>2</sup> Alzheimer disease vs. non-Alzheimer disease;  $P = 0.06$ ). As expected, the frequency and the extent of islet amyloid was greater in type 2 diabetes (group 3) versus non-type 2 diabetes (group 4;  $P < 0.001$ ; Fig. 2).

Inclusion of cases in this autopsy protocol was blinded with respect to the presence or absence of diabetes but with the requirement that FPG be documented. Subsequent analysis of the FPG concentrations revealed that the prevalence of type 2 diabetes (FPG  $>126$  mg/dl) in the Alzheimer disease group was 32% and in non-Alzheimer disease cases was 14% ( $P = 0.15$ ). The mean FPG in Alzheimer disease was not higher than in control subjects ( $126 \pm 8$  vs.  $110 \pm 6$  mg/dl;  $P = 0.09$ ).

**Protocol 4: brain amyloid in type 2 diabetes.** The density of diffuse or neuritic plaques or NFT was not different between patients with type 2 diabetes versus nondiabetic control subjects ( $P = 0.07$ ,  $P = 0.3$ , and  $P =$

TABLE 3  
Brain pathology

	Median	Range	<i>P</i> value
Diffuse plaques			
Type 2 diabetes	0.20	0.0–11.8	0.07
Non-type 2 diabetes	0	0.0–11.6	
Neuritic plaques			
Type 2 diabetes	0	0.0–9.3	0.3
Non-type 2 diabetes	0	0.0–4.8	
NFT			
Type 2 diabetes	0	0.0–1.2	0.4
Non-type 2 diabetes	0	0.0–0.8	

0.4, respectively; Table 3). As expected, the density of neuritic plaques, diffuse plaques, and NFT was greater ( $P < 0.05$ ) in Alzheimer disease cases (group 1) versus non-Alzheimer disease (group 2).

In 22 of 28 type 2 diabetes cases, the year of diagnosis of diabetes was documented. Diffuse plaques were detected in 12 and neuritic plaques in 7 of these 22 cases of type 2 diabetes with a documented age of onset of diabetes. There was a positive relationship between duration of known diabetes and the extent of diffuse plaques ( $r_s = 0.8$ ,  $P < 0.001$ ) or neuritic plaques ( $r_s = 0.9$ ,  $P < 0.01$ ) in these cases (Fig. 3). In contrast, in neither type 2 diabetes nor non-type 2 diabetes was there a correlation with the density of either of these plaques and the age at death.




FIG. 3. Protocol 4: relationship between the density of diffuse plaques ( $r_s = 0.8$ ,  $P < 0.001$ ; *top*) or neuritic plaques ( $r_s = 0.9$ ,  $P < 0.01$ ; *bottom*) versus the duration of diabetes in patients with type 2 diabetes. Cases were included only when the duration of diabetes was documented and the respective plaque type was detected (y did not equal zero).



differences in populations and inclusion criteria likely contribute to the conflicting epidemiological data in this field. Some studies suggest that the prevalence of Alzheimer disease is increased in type 2 diabetes (58–60), whereas in others, it has been reported as decreased (61–66) or comparable (48,49,67–71). A confounding factor in these studies (including the current one) is that Alzheimer disease is often accompanied by a decreased BMI presumed to be a result of decreased food intake. Because the most potent risk factor for development of type 2 diabetes is an increased BMI, it is possible that an association between these conditions has been obscured by the relative protective effect of a decreased BMI in Alzheimer disease. Alternatively, it is possible that people with Alzheimer disease exercise less and therefore have decreased insulin sensitivity and increased risk for type 2 diabetes. As type 2 diabetes tends to develop at a younger age than Alzheimer disease and is associated with a decreased life expectancy, early death from complications of diabetes might obscure subsequent development of Alzheimer disease. The current pathology studies are unique inasmuch as the Alzheimer disease and non-Alzheimer disease groups were fully characterized both in life and by autopsy, and so although the numbers are small, it is provocative that there is a distinct increase in risk of islet amyloid in patients with Alzheimer disease despite a lower BMI. The clinical data (protocols 1 and 2) are also community-based cases that have been defined extensively with respect to the presence or absence of dementia and followed over a relatively long term (33). It is of interest that a population-based study from the same region showed an association between type 2 diabetes and Alzheimer disease (59). Whereas the former study examined records of all known cases of type 2 diabetes in the Rochester area at the time of the study for a diagnosis of dementia and Alzheimer disease (1,455 cases), the present study was focused on a much smaller cohort of patients with Alzheimer disease (100 cases) and control subjects (138 cases) enrolled in the ADPR (33), wherein the diagnosis of Alzheimer disease was rigorously established, and then the same patients were followed annually in the study thereafter and when deceased were included in the autopsy studies. One other factor that might have caused discrepancies between reported studies is the changing definition of diabetes. The present study uses the criteria adopted for FPG concentrations in 1997 by an expert committee convened by the American Diabetes Association (72). As a consequence of this report, the plasma glucose concentration required to establish the diagnosis of diabetes was decreased from 140 mg/dl to 126 mg/dl. Furthermore, a high-risk group was established for the subsequent development of diabetes with an FPG concentration of 110–125 mg/dl. Studies that used the higher values for diagnosis of diabetes would report lower prevalence rates in both Alzheimer disease and control subjects and possibly not observe differences between groups that might be evident with the criteria used here.

Another potential confounding factor in previous as well as the present studies is recruitment bias. All studies performed at major tertiary referral centers such as the Mayo Clinic are subject to such bias. Efforts were made to minimize this in the present clinical studies by recruitment

of patients from the local community from the community clinics of the Mayo Medical Center. Patients were therefore attending the Mayo Clinic community clinics for primary care when they were recruited for either the Alzheimer disease or control groups of the clinical studies. Nonetheless, other recruitment bias may be introduced in a study such as ours by the failure of affected patients to seek medical care and therefore be unavailable for consideration. In the present study, there is a greater proportion of women than men in the clinical studies, which might be in part a reflection of recruitment bias but also potentially be due to the shorter life span of men than women once Alzheimer disease is diagnosed. Autopsy studies of Alzheimer disease cases and control subjects (for islet amyloid) would be subject to the same ascertainment bias as the ADPR since the cases were in the ADPR until death. In autopsy studies of type 2 diabetes cases versus control subjects for brain amyloid, we sought to minimize deliberate bias by including most recent autopsies in reverse sequence from cases that were appropriate for inclusion for these criteria. People who have an autopsy are of course in themselves a subgroup of the general population, so bias has to be considered. Notwithstanding these limitations, we do have the opportunity of presenting autopsy data from cases that were well characterized in life compared with most autopsy studies.

In conclusion, we report that there is an increased prevalence of both type 2 diabetes and IFG in a community cohort of patients with Alzheimer disease followed in Olmsted County, Rochester, Minnesota. We also report increased islet amyloid in patients with Alzheimer disease compared with control subjects. However, we did not observe an increased frequency of brain amyloid in cases of type 2 diabetes, although in cases of type 2 diabetes that did have brain amyloid, the extent of this amyloid increased with longer duration of diabetes, a correlate that did not extend to the age of patients with type 2 diabetes. Taken together, these clinical and pathological studies support a possible link between the neurodegenerative processes that lead to loss of cortical brain cells in Alzheimer disease and the loss of  $\beta$ -cells in type 2 diabetes.

#### ACKNOWLEDGMENTS

This study was funded by grants from the National Institute on Aging, the Mayo ADPR (AG 06786), the Mayo Alzheimer Disease Research Center (AG 16574 to J.E.P. and R.C.P. and DK59579 to P.C.B.), and the Larry Hillblom Foundation (to P.C.B.).

We acknowledge the excellent technical assistance of Jane Kahl and Karen Laakso, the staff of the Mayo Alzheimer Disease Research Center, and the excellent editorial assistance of Kim Denkers. We thank Robert Rizza for suggestions and support.

#### REFERENCES

1. Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. *Diabetologia* 15:417–421, 1978
2. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. *Diabetes Res* 9:151–159, 1988
3. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. *Proc Natl Acad Sci U S A* 84:8628–8632, 1987



4. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. *Proc Natl Acad Sci U S A* 84:3881-3885, 1987
5. Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P: Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. *Am J Pathol* 130:1-8, 1988
6. Braak H, Braak E: The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. *Neurosci Res* 15:6-31, 1992
7. Glenner GG, Wong CW: Alzheimer disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun* 120:885-890, 1984
8. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A* 82:4245-4249, 1985
9. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K: Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer disease contain the same protein as the amyloid of plaque cores and blood vessels. *EMBO J* 4:2757-2763, 1985
10. Bahmanyar S, Higgins GA, Goldgaber D, Lewis DA, Morrison JH, Wilson MC, Shankar SK, Gajdusek DC: Localization of amyloid beta protein messenger RNA in brains from patients with Alzheimer disease. *Science* 237:77-80, 1987
11. Goedert M: Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer disease. *EMBO J* 6:3627-3632, 1987
12. Card JP, Meade RP, Davis LG: Immunocytochemical localization of the precursor protein for beta-amyloid in the rat central nervous system. *Neuron* 1:835-846, 1988
13. Shivers BD, Hilbich C, Multhaup G, Salbaum M, Beyreuther K, Seeburg PH: Alzheimer disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. *EMBO J* 7:1365-1370, 1988
14. Van Broeckhoven C, Genthe AM, Vandenberghe A, Horsthemke B, Backhovens H, Raeymaekers P, Van Hul W, Wehnert A, Gheuens J, Cras P, et al: Failure of familial Alzheimer disease to segregate with the A4-amyloid gene in several European families. *Nature* 329:153-155, 1987
15. Tanzi RE, St George-Hyslop PH, Haines JL, Polinsky RJ, Nee L, Foncin JF, Neve RL, McClatchey AI, Conneally PM, Gusella JF: The genetic defect in familial Alzheimer disease is not tightly linked to the amyloid beta-protein gene. *Nature* 329:156-157, 1987
16. St George-Hyslop PH, Haines JL, Farrer LA, Polinsky R, Van Broeckhoven C, Goate A, McLachlan DR, Orr H, Bruni AC, Sorbi S, et al: Genetic linkage studies suggest that Alzheimer disease is not a single homogeneous disorder: FAD Collaborative Study Group. *Nature* 347:194-197, 1990
17. Wilson PW, Anderson KM, Kannel WB: Epidemiology of diabetes mellitus in the elderly: the Framingham Study. *Am J Med* 80(5A):3-9, 1986
18. Barnett AH, Eff C, Leslie RD, Pyke DA: Diabetes in identical twins: a study of 200 pairs. *Diabetologia* 20:87-93, 1981
19. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD: Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. *Diabetologia* 30:763-768, 1987
20. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K: Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer disease. *J Mol Biol* 218:149-163, 1991
21. Glenner GG, Eanes ED, Wiley CA: Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. *Biochem Biophys Res Commun* 155:608-614, 1988
22. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. *Nature* 368:756-760, 1994
23. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H: Amyloid peptides are toxic via a common oxidative mechanism. *Proc Natl Acad Sci U S A* 92:1989-1993, 1995
24. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL: Human islet amyloid polypeptide expression in COS-1 cells: a model of intracellular amyloidogenesis. *Am J Pathol* 147:609-616, 1995
25. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. *Diabetes* 48:491-498, 1999
26. Mirzabekov TA, Lin MC, Kagan BL: Pore formation by the cytotoxic islet amyloid peptide amylin. *J Biol Chem* 271:1988-1992, 1996
27. Lashuel HA, Hartley D, Petre BM, Waltz T, Lansbury PT: Neurodegenerative disease: amyloid pores from pathogenic mutations. *Nature* 418:291, 2002
28. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC: Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and  $\beta$ -cell dysfunction. *Diabetes* 45:1094-1101, 1996
29. O'Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC: Islet amyloid polypeptide in human insulinomas: evidence for intracellular amyloidogenesis. *Diabetes* 43:329-336, 1994
30. Craig EA, Weissman JS, Horwich AL: Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. *Cell* 78:365-372, 1994
31. Butler PC, Eberhardt NL, O'Brien TD: Islet amyloid polypeptide (IAPP) and insulin secretion. In *Molecular Biology of Diabetes*. Draznin B, LeRoith D, Eds. Totowa, NJ, Humana Press, 1994, p. 381-398
32. Schwartz P: Senile cerebral, pancreatic insular and cardiac amyloidosis. *Trans N Y Acad Sci* 27:393-413, 1965
33. Petersen RC, Kokmen E, Tangalos E, Ivnik RJ, Kurland LT: Mayo Clinic Alzheimer disease patient registry. *Aging* 2:408-415, 1990
34. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A: The Consortium to Establish a Registry for Alzheimer Disease (CERAD): Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer disease. *Neurology* 45:461-466, 1995
35. Betsholtz C, Christmansson L, Engstrom U, Rorsman F, Svensson V, Johnson KH, Westermark P: Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. *FEBS Lett* 251:261-264, 1989
36. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. *Proc Natl Acad Sci U S A* 87:5036-5040, 1990
37. Zhang S, Liu J, Saafi EL, Cooper GJ: Induction of apoptosis by human amylin in RINm5F islet beta-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. *FEBS Lett* 455:315-320, 1999
38. Zhang S, Liu J, MacGibbon G, Dragunow M, Cooper GJ: Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. *J Mol Biol* 324:271-285, 2002
39. Bai JZ, Saafi EL, Shang S, Cooper GJ: Role of Ca<sup>2+</sup> in apoptosis evoked by human amylin in pancreatic islet beta-cells. *Biochem J* 343:53-61, 1999
40. Tucker HM, Rydel RE, Wright S, Estus S: Human amylin induces "apoptotic" pattern of gene expression concomitant with cortical neuronal apoptosis. *J Neurochem* 71:506-516, 1998
41. Laczko I, Holly S, Konya Z, Soos K, Varga J, Hollosi M, Penke B: Conformational mapping of amyloid peptides from the putative neurotoxic 25-35 region. *Biochem Biophys Res Commun* 205:120-126, 1994
42. Kaye R, Head E, Thompson JL, McIntire TM, Milton SC, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* 300:486-489, 2003
43. Blake MJ, Edelman R, Feulner GJ, Nortone DD, Holbrook NJ: Stress-induced heat shock protein 70 expression in adrenal cortex: an adrenocorticotropic hormone-sensitive, age-dependent response. *Proc Natl Acad Sci U S A* 88:9873-9877, 1991
44. Finch CE, Cohen DM: Aging, metabolism, and Alzheimer disease: review and hypothesis. *Exp Neurol* 143:82-102, 1997
45. Yan SD, Stern D, Schmidt AM: What's the rage? The receptor for advanced glycation and end products (RAGE) and the dark side of glucose. *Eur J Clin Invest* 27:179-181, 1997
46. Sasaki N, Toki S, Chowei H, Saito T, Nakao N, Hayashi Y, Takeuchi M, Makita Z: Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer disease. *Brain Res* 888:256-262, 2001
47. Heitner J, Dickson D: Diabetics do not have increased Alzheimer-type pathology with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. *Neurology* 49:1306-1311, 1997
48. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, Foley D, Blanchette PL, Harris T, Chen R, White LR: Longitudinal association of vascular and Alzheimer dementias, diabetes, and glucose tolerance. *Neurology* 52:971-975, 1999
49. MacKnight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer disease and vascular cognitive impairment in the Canadian study of health and aging. *Dement Geriatr Cogn Disord* 14:77-83, 2002
50. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M-R, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 24:683-689, 2001
51. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z: Advanced

- glycation end products in Alzheimer disease and other neurodegenerative diseases. *Am J Pathol* 153:1149–1155, 1998
52. Mast H, Thompson JL, Lee SH, Mohr JP, Sacco RL: Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. *Stroke* 26:30–33, 1995
  53. Tatemichi TK, Desmond DW, Paik M, Figueroa M, Gropen TI, Stern Y, Sano M, Remien R, Williams JB, Mohr JP, et al.: Clinical determinants of dementia related to stroke. *Ann Neurol* 33:568–575, 1993
  54. Desmond DW, Tatemichi TK, Paik M, Stern Y: Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. *Arch Neurol* 50:162–166, 1993
  55. McCall AL: The impact of diabetes on the NCS. *Diabetes* 41:557–570, 1992
  56. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gibsen WH: Cerebral function in diabetes mellitus. *Diabetologia* 37:643–650, 1994
  57. Langen SJ, Deary IJ, Hepburn DA, Frier BM: Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus. *Diabetologia* 34:337–344, 1991
  58. Ott A, Stolk RP, van Harskamp F, Pols H, Hofman A, Breteler M: Diabetes mellitus and the risk of dementia: the Rotterdam study. *Neurology* 53:1937–1942, 1999
  59. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ: The risk of dementia among persons with diabetes mellitus: a population based cohort study. *Am J Epidemiol* 145:301–308, 1997
  60. Luchsinger JA, Tang M-X, Yaakov S, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol* 154:635–641, 2001
  61. Bucht G, Adolfsson R, Lithner F, Winblad B: Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. *Acta Med Scand* 213:387–392, 1983
  62. Wolf-Klein GP, Silversone FA, Brod MS, Levy A, Foley CJ, Termotto V, Breuer J: Are Alzheimer patients healthier? *J Am Geriatr Soc* 36:219–224, 1988
  63. Ferini-Strambi L, Smirne S, Garanchini P, Pinto P, Franceschi M: Clinical and epidemiological aspects of Alzheimer disease with presenile onset: a case control study. *Neuroepidemiology* 9:39–49, 1990
  64. Landin K, Blennow K, Wallin A, Gottfries C-G: Low blood pressure and blood glucose levels in Alzheimer disease: evidence for a hypometabolic disorder? *J Intern Med* 233:357–363, 1993
  65. Mortel KF, Wood S, Pavol MA, Meyer JS, Rexer JL: Analysis of familial and individual risk factors among patients with ischemic vascular dementia and Alzheimer disease. *Angiology* 44:599–605, 1993
  66. Neilson KA, Nolan JH, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW: Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer disease? *J Am Geriatr Soc* 44:1–8, 1996
  67. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T: Alzheimer disease: a study of epidemiological aspects. *Ann Neurol* 15:335–341, 1984
  68. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC: A case controlled study of Alzheimer disease in Australia. *Neurology* 40:1698–1707, 1990
  69. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ: Clinical risk factors for Alzheimer disease: a population based case-control study. *Neurology* 41:1393–1397, 1991
  70. Thorpe J, Widman LP, Wallin A, Beiswanger J, Blumenthal HT: Comorbidity of other chronic age-dependent diseases in dementia. *Aging Clin Exp Res* 6:159–166, 1994
  71. Curb JD, Roderiquez BL, Petrovich H, Masaki KH, Burchfiel CM, Ross W, Chen R, Harris T, White LR: The relationship of diabetes and glucose tolerance to Alzheimer disease and vascular dementia (Abstract 488). *Neurobiol Aging* 17 (Suppl.):S122, 1996
  72. The expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 20:1183–1197, 1997